Announcing the Good Participatory Practice Body of Evidence

We are thrilled to announce the Good Participatory Practice (GPP) Body of Evidence, a new online clearinghouse of case studies and analyses demonstrating the power of GPP, along with tools, templates and trainings for GPP implementation. The resources we’ve gathered for this much-needed “one-stop GPP shop” can be used to show the impact of GPP to date, how it can be measured going forward, and its practical application in real-time.  

The Good Participatory Practice Guidelines have been shaping and improving HIV prevention research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.  

Over the past 16 years, the original GPP guidelines for HIV prevention have been issued in 10 languages and adapted to other disease areas, including tuberculosis, COVID-19, and emerging pathogens. GPP has given rise to a robust global community of practice, with an expansive history of lessons learned and success stories for the world to build upon. 

But GPP implementation is far from easy. Because GPP looks different in every context and outcomes can be difficult to quantify, engagement work is often seen as secondary to clinical processes, and therefore undervalued and under-resourced. The GPP Body of Evidence demonstrates the contribution of GPP to the research enterprise, and the professionalization of GPP implementation. 

Rest assured that this is not a one-off effort! Stay tuned for a webinar series in 2024 with key partners including WHO and Wellcome Trust that will highlight critical issues in stakeholder engagement in research, linking to corresponding resources from the Body of Evidence. And we’ll be keeping the Body of Evidence up to date – so please reach out if you have resources to add.  

It’s time for GPP to become an international standard for clinical research. Making that case and making it happen, using the GPP Body of Evidence, has never been easier.  

Avac Event

African Civil Society Mobilization for PEPFAR Reauthorization

Tuesday, November 28 at 7:00 AM ET

Moderator: Richard Muko, Regional Implementation Advocacy Manager, AVAC

Panelists: Joan Chamungu, Tanzanian Network of Women Living with HIV, Lawrence Khonyongwa, Malawi Network of People of Living with HIV, TBC, African Network of Youth Living with HIV, Annette Gaudino, Advocacy Coalition Manager, GAPP

Hosted by African Network of Youth Living with HIV (AY+), East African Network of AIDS Serving Organizations (EANNASO), Key Populations Trans-National Collaboration (KPTNC) and Coalition to build Momentum, Power, Activism, Strategy & Solidarity (COMPASS)

Join civil society organizations in PEPFAR recipient countries to discuss the status and political context of the current reauthorization and mobilize to call on the US Congress to recommit this life sustaining program. Bring your questions and please share this invitation widely in your relevant networks.

Recording / Slides

Results from STI Landscaping Analyses in East and Southern Africa—Parts 1 and 2

Hear results from STI landscaping projects conducted in seven different countries from East and Southern Africa that explored needs for STI vaccines and diagnostics.

Part 1 Recording / Part 2 Recording

Latu Human Rights Foundation Slides / ACTS 101 Uganda Slides / Journalists Association Against AIDS (JournAIDS) Slides/ Lesotho Network of AIDS Service Organizations (LENASO) Slides / HIV Survivors and Partners Network (HIVSPN) Slides / Pangaea Zimbabwe AIDS Trust (PZAT) Slides / Nyanza Reproductive Health Society (NRHS) Slides

New Episode of the Px Pulse Podcast

The intersection of HIV research and pregnancy

AVAC’s Px Pulse podcast has a new episode: Inclusion of Pregnant and Lactating People in HIV Research: What you need to know. 

People who are pregnant or lactating (PLP) have historically been excluded from research because of concerns for the developing fetus. But this has led to a dearth of data on new interventions against health threats for this population. In the case of HIV, pregnancy raises the risk of acquiring HIV by up to three times, but providers often do not have the data to know whether a new intervention is safe or how it will work for pregnant patients. As a result, PLP and their physicians are left to make difficult decisions around the use of proven HIV prevention products as they await more data specific to pregnancy and lactation. 

But change is in the air. Champions for the inclusion of PLP in research are paving the way for a paradigm shift— one that will redefine this population from needing protection from research to being better protected through research. In this episode of Px Pulse, AVAC’s Manju Chatani-Gada takes us through conversations with a trial participant who became pregnant, researchers, policy-makers and donors to understand why this population gets excluded, the impact it has, and what to do about it.   

Tune in to hear

  • Dr. Anne Drapkin Lyerly, Principal Investigator of the PHASES Project to advance equitable inclusion of pregnant women in HIV research and its follow-on project, PREPARE, focused on ethical HIV research in adolescents who are pregnant.  
  • Elisia Madende, Trial participant in the HPTN 084 trial in Zimbabwe
  • Dr. Ashley Lima, Health Science Specialist and Lead Technical Advisor for Socio-behavioral Research – USAID Office of HIV/AIDS Research Division 
  • Dr. Takunda Sola, HIV Prevention and Key Populations Medical Officer- Zimbabwe MoH AIDS/TB Unit 

Advocacy resources 

Civil Society Analysis: Negotiating Text of the WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response (WHO Pandemic Agreement)

This analysis is a compilation of recommendations from civil society and community organisations on the DRAFT Negotiating Text of the WHO convention, agreement or other international instrument on pandemic prevention, preparedness, and response (WHO Pandemic Agreement).

Read the full analysis here.

Avac Event

Pandemic Accord Briefing for Civil Society & Community Partners

The Pandemic Accord negotiations are ongoing, and should come to fruition next year. What do they mean for your work, your country, and the future of global health?

On Tuesday, November 21, 8:00 to 9:30 AM EST / 2:00 to 3:30 PM CEST, advocates came together to discuss two years of talks and what’s next to progress global health equity.

Avac Event

Africa Health R&D Week

Save the Date: Tuesday, November 21 to Friday, November 24

Africa Health R&D Week 2023 is designed to recognize achievements and step up advocacy for sustainable financing of health R&D through domestic resource mobilization (DRM) in Africa.

Inaugurated in 2022, the Africa Health R&D Week is a continental movement that builds bridges between researchers, policy makers, regulators, civil society advocates and community members committed to Africa’s health transformation through health R&D, and innovation. 

This year the four-day virtual forum focuses on the need for sustainable support for vaccine development and manufacturing in low- and middle-income countries (LMICs), including Domestic Resource Mobilization (DRM). The 2023 edition will leverage South-South learning, by eliciting/ linking lessons and experiences from Asia and Africa.

Hosted by IAVI, in partnership with  AVAC under the USAID-funded Coalition to Accelerate and Support Prevention Research (CASPR), the forum will discuss:

Day 1 – The aspirations, the reality and the gaps in Vaccine Manufacturing in LMICs (underscoring Africa)

Day 2 – African Countries contribution to the continental vision (Case studies of building manufacturing capacity) 

Day 3 – Industry perspectives from Africa and Asia: Opportunities and challenges, and addressing the issue  of sustainability 

Day 4 – Advocates workshop to develop an advocacy roadmap to champion vaccine manufacturing

Avac Event

PrEP Resources Showcase

Monday, November 20, 8:00 to 9:30 AM ET

This dynamic, workshop-style showcase was the first of a series that featured multimedia presentations that took participants through key PrEP resources including: A toolkit to ensure programs related to sexual and reproductive health (SRH) and HIV prevention are well designed to reach and support adolescent girls and young women. Comprehensive databases for tracking PrEP uptake, Implementation research and other critical data by product, country, and population.  

Small groups had opportunities to take deep dives into each of the above resources, and explore how they might use these in their work. Additionally, participants provided input on what resources are still needed, collaborate on how to improve and disseminate what exists, and support the development of evidence and networks to advance HIV prevention.

Global PrEP Tracker video / Integrated Study Dashboard video / Breaking the Cycle Toolkit video

Avac Event

Spotlight on New PrEP Tools and Data: From R&D to access

Tuesday, November 28

Between the recent accelerated growth in global PrEP initiations, and the introduction of new PrEP products like cabotegravir and the dapivirine vaginal ring, the field of PrEP data has never been more exciting or more complex. Staying on top of the latest advances is key for advocates, researchers, funders, and others working in HIV prevention to do their job effectively—but how can you navigate the vast amount of PrEP data online? AVAC, the Medicines Patent Pool (MPP), and Unitaid presented information on three important online PrEP resources and understand how they can support and enhance your work:

  • PrEPWatch.org: the one stop shop for PrEP resources to support introduction and scale-up, including the PrEPTracker, the only place to find information on global PrEP initiations online
  • Long Acting Therapeutics Patents and Licenses Database (LAPaL): LAPaL is the go-to resource to learn about long-acting therapeutics, their patent landscape, development and regulatory status
  • Access to Medicines Tracker: the go-to place for quarterly-updated insights on regulatory filings, regulatory approvals, and product supplies of MPP-licensed generic medicines at the country level.

Recording / Slides

Blueprint for Sexual & Reproductive Health, Rights & Justice

AVAC joined more than 100 organizations to endorse the 2023 Blueprint for Sexual and Reproductive Health, Rights, and Justice Policy Agenda. Check it out to see recommendations to the US Executive Branch that would protect and expand access to sexual and reproductive health, rights and justice around the world. This Blueprint comes as several major threats to sexual health, rights and justice are gaining ground: the loss of abortion access and gender-affirming care in the US, and criminalization of LGBTQ people around the world.